301 related articles for article (PubMed ID: 34917096)
1. Endothelial Dysfunction in Fabry Disease Is Related to Glycocalyx Degradation.
Pollmann S; Scharnetzki D; Manikowski D; Lenders M; Brand E
Front Immunol; 2021; 12():789142. PubMed ID: 34917096
[TBL] [Abstract][Full Text] [Related]
2. Mutation-specific Fabry disease patient-derived cell model to evaluate the amenability to chaperone therapy.
Lenders M; Stappers F; Niemietz C; Schmitz B; Boutin M; Ballmaier PJ; Zibert A; Schmidt H; Brand SM; Auray-Blais C; Brand E
J Med Genet; 2019 Aug; 56(8):548-556. PubMed ID: 31010832
[TBL] [Abstract][Full Text] [Related]
3. Globotriaosylsphingosine accumulation and not alpha-galactosidase-A deficiency causes endothelial dysfunction in Fabry disease.
Namdar M; Gebhard C; Studiger R; Shi Y; Mocharla P; Schmied C; Brugada P; Lüscher TF; Camici GG
PLoS One; 2012; 7(4):e36373. PubMed ID: 22558451
[TBL] [Abstract][Full Text] [Related]
4. Pathogenesis and Molecular Mechanisms of Anderson-Fabry Disease and Possible New Molecular Addressed Therapeutic Strategies.
Tuttolomondo A; Simonetta I; Riolo R; Todaro F; Di Chiara T; Miceli S; Pinto A
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576250
[TBL] [Abstract][Full Text] [Related]
5. Fabry Disease: The Current Treatment Landscape.
Lenders M; Brand E
Drugs; 2021 Apr; 81(6):635-645. PubMed ID: 33721270
[TBL] [Abstract][Full Text] [Related]
6. Enhanced thrombospondin-1 causes dysfunction of vascular endothelial cells derived from Fabry disease-induced pluripotent stem cells.
Do HS; Park SW; Im I; Seo D; Yoo HW; Go H; Kim YH; Koh GY; Lee BH; Han YM
EBioMedicine; 2020 Feb; 52():102633. PubMed ID: 31981984
[TBL] [Abstract][Full Text] [Related]
7. Neutralising anti-drug antibodies in Fabry disease can inhibit endothelial enzyme uptake and activity.
Stappers F; Scharnetzki D; Schmitz B; Manikowski D; Brand SM; Grobe K; Lenders M; Brand E
J Inherit Metab Dis; 2020 Mar; 43(2):334-347. PubMed ID: 31587315
[TBL] [Abstract][Full Text] [Related]
8. Chaperone Therapy in Fabry Disease.
Weidemann F; Jovanovic A; Herrmann K; Vardarli I
Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163813
[TBL] [Abstract][Full Text] [Related]
9. Detailed epitope mapping of neutralizing anti-drug antibodies against recombinant α-galactosidase A in patients with Fabry disease.
Scharnetzki D; Stappers F; Lenders M; Brand E
Mol Genet Metab; 2020; 131(1-2):229-234. PubMed ID: 32888778
[TBL] [Abstract][Full Text] [Related]
10. Complement activation and cellular inflammation in Fabry disease patients despite enzyme replacement therapy.
Laffer B; Lenders M; Ehlers-Jeske E; Heidenreich K; Brand E; Köhl J
Front Immunol; 2024; 15():1307558. PubMed ID: 38304433
[TBL] [Abstract][Full Text] [Related]
11. Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study.
Hughes DA; Nicholls K; Shankar SP; Sunder-Plassmann G; Koeller D; Nedd K; Vockley G; Hamazaki T; Lachmann R; Ohashi T; Olivotto I; Sakai N; Deegan P; Dimmock D; Eyskens F; Germain DP; Goker-Alpan O; Hachulla E; Jovanovic A; Lourenco CM; Narita I; Thomas M; Wilcox WR; Bichet DG; Schiffmann R; Ludington E; Viereck C; Kirk J; Yu J; Johnson F; Boudes P; Benjamin ER; Lockhart DJ; Barlow C; Skuban N; Castelli JP; Barth J; Feldt-Rasmussen U
J Med Genet; 2017 Apr; 54(4):288-296. PubMed ID: 27834756
[TBL] [Abstract][Full Text] [Related]
12. α-Galactosidase a Deficiency in Fabry Disease Leads to Extensive Dysregulated Cellular Signaling Pathways in Human Podocytes.
Jehn U; Bayraktar S; Pollmann S; Van Marck V; Weide T; Pavenstädt H; Brand E; Lenders M
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768768
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of Neutralizing Anti-drug Antibody Formation and Clinical Relevance on Therapeutic Efficacy of Enzyme Replacement Therapies in Fabry Disease.
Lenders M; Brand E
Drugs; 2021 Nov; 81(17):1969-1981. PubMed ID: 34748189
[TBL] [Abstract][Full Text] [Related]
14. Treatment of Fabry Disease management with migalastat-outcome from a prospective 24 months observational multicenter study (FAMOUS).
Lenders M; Nordbeck P; Kurschat C; Eveslage M; Karabul N; Kaufeld J; Hennermann JB; Patten M; Cybulla M; Müntze J; Üçeyler N; Liu D; Das AM; Sommer C; Pogoda C; Reiermann S; Duning T; Gaedeke J; von Cossel K; Blaschke D; Brand SM; Mann WA; Kampmann C; Muschol N; Canaan-Kühl S; Brand E
Eur Heart J Cardiovasc Pharmacother; 2022 May; 8(3):272-281. PubMed ID: 35512362
[TBL] [Abstract][Full Text] [Related]
15. Dissociation of globotriaosylceramide and impaired endothelial function in α-galactosidase-A deficient EA.hy926 cells.
Kaissarian N; Kang J; Shu L; Ferraz MJ; Aerts JM; Shayman JA
Mol Genet Metab; 2018 Dec; 125(4):338-344. PubMed ID: 30413389
[TBL] [Abstract][Full Text] [Related]
16. Agalsidase-β should be proposed as first line therapy in classic male Fabry patients with undetectable α-galactosidase A activity.
Nowak A; Dormond O; Monzambani V; Huynh-Do U; Barbey F
Mol Genet Metab; 2022; 137(1-2):173-178. PubMed ID: 36087505
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients.
Tsuboi K; Yamamoto H
BMC Pharmacol Toxicol; 2017 Jun; 18(1):43. PubMed ID: 28592315
[TBL] [Abstract][Full Text] [Related]
18. Flow Cytometry-Based Assay to Detect Alpha Galactosidase Enzymatic Activity at the Cellular Level.
Fekete N; Li LK; Kozma GT; Fekete G; Pállinger É; Kovács ÁF
Cells; 2024 Apr; 13(8):. PubMed ID: 38667321
[TBL] [Abstract][Full Text] [Related]
19. Glucosylceramide synthase inhibition with lucerastat lowers globotriaosylceramide and lysosome staining in cultured fibroblasts from Fabry patients with different mutation types.
Welford RWD; Mühlemann A; Garzotti M; Rickert V; Groenen PMA; Morand O; Üçeyler N; Probst MR
Hum Mol Genet; 2018 Oct; 27(19):3392-3403. PubMed ID: 29982630
[TBL] [Abstract][Full Text] [Related]
20. Fasudil alleviates the vascular endothelial dysfunction and several phenotypes of Fabry disease.
Choi JB; Seol DW; Do HS; Yang HY; Kim TM; Byun YG; Park JM; Choi J; Hong SP; Chung WS; Suh JM; Koh GY; Lee BH; Wee G; Han YM
Mol Ther; 2023 Apr; 31(4):1002-1016. PubMed ID: 36755495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]